MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics to host a Capital Markets Update
on Wednesday, September 11

ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Update for investors and analysts live from New York on Wednesday, September 11 from 2024, from 9:00 – 10:30 EST/06:00 – 08:30 PST/14:00 – 16:30 CET
The event will provide business updates from MoonLake’s CEO Jorge Santos da Silva, CSO Kristian Reich and CFO Matthias Bodenstedt and include details on the Phase 3 programs for our investigational Nanobody^® sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA).

Read more at globenewswire.com